Nahdi Medical Company (4164.SR)
SAR 113.0
(-0.88%)
SAR 113.0
(-0.88%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 870.56 Million SAR | 9.89% |
| 2022 | 792.23 Million SAR | -20.11% |
| 2021 | 991.64 Million SAR | 19.63% |
| 2020 | 828.95 Million SAR | -15.79% |
| 2019 | 984.4 Million SAR | 0.0% |
| 2018 | - SAR | 0.0% |
| 2017 | - SAR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 955.68 Million SAR | 0.0% |
| 2024 Q1 | 832.71 Million SAR | 0.0% |
| 2023 Q2 | 753.04 Million SAR | -8.4% |
| 2023 Q1 | 822.13 Million SAR | 3.77% |
| 2023 FY | 870.56 Million SAR | 9.89% |
| 2023 Q4 | 870.56 Million SAR | 15.22% |
| 2023 Q3 | 755.54 Million SAR | 0.33% |
| 2022 Q4 | 792.23 Million SAR | -18.44% |
| 2022 Q3 | 971.29 Million SAR | -13.21% |
| 2022 Q2 | 1.11 Billion SAR | -3.69% |
| 2022 Q1 | 1.16 Billion SAR | 17.17% |
| 2022 FY | 792.23 Million SAR | -20.11% |
| 2021 FY | 991.64 Million SAR | 19.63% |
| 2021 Q3 | 1.01 Billion SAR | 9.27% |
| 2021 Q2 | 929.29 Million SAR | 0.0% |
| 2021 Q1 | - SAR | -100.0% |
| 2021 Q4 | 991.64 Million SAR | -2.35% |
| 2020 Q1 | - SAR | 0.0% |
| 2020 FY | 828.95 Million SAR | -15.79% |
| 2020 Q4 | 828.95 Million SAR | 0.0% |
| 2019 FY | 984.4 Million SAR | 0.0% |
| 2018 FY | - SAR | 0.0% |
| 2017 FY | - SAR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 3.16 Million SAR | -27371.605% |
| Al-Dawaa Medical Services Company | 1.44 Billion SAR | 39.882% |
| Al-Razi Medical Co. | 1.77 Million SAR | -48942.457% |
| Almujtama Alraida Medical Co. | - SAR | -Infinity% |